<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="editorial" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">TAB</journal-id>
<journal-id journal-id-type="hwp">sptab</journal-id>
<journal-title>Therapeutic Advances in Musculoskeletal Disease</journal-title>
<issn pub-type="ppub">1759-720X</issn>
<issn pub-type="epub">1759-7218</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/1759720X13491853</article-id>
<article-id pub-id-type="publisher-id">10.1177_1759720X13491853</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Editorial</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Important issues at heart: cardiovascular risk management in rheumatoid arthritis</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Roubille</surname><given-names>Camille</given-names></name>
<aff id="aff1-1759720X13491853">Osteoarthritis Research Unit, University of Montreal Hospital Research Center (CRCHUM), Notre-Dame Hospital, 1560 Sherbrooke Street East, Montreal, QC, Canada H2L 4M1</aff>
</contrib>
<contrib contrib-type="author">
<name><surname>Haraoui</surname><given-names>Boulos</given-names></name>
<aff id="aff2-1759720X13491853">Department of Rheumatology, University of Montreal, Institut de Rhumatologie de Montreal, Montreal, QC, Canada</aff>
</contrib>
</contrib-group>
<author-notes>
<corresp id="corresp1-1759720X13491853"><email>camille.roubille@gmail.com</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>8</month>
<year>2013</year>
</pub-date>
<volume>5</volume>
<issue>4</issue>
<fpage>163</fpage>
<lpage>165</lpage>
<permissions>
<copyright-statement>© The Author(s), 2013</copyright-statement>
<copyright-year>2013</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
</article-meta>
</front>
<body>
<p>Atherosclerosis remains the predominant cause of cardiovascular diseases (CVDs) and heart failure, which are the leading causes of death worldwide. It is now well established that patients with rheumatoid arthritis (RA) experience an accelerated atherosclerosis increasing their risk of CVD and related mortality compared with the general population [<xref ref-type="bibr" rid="bibr9-1759720X13491853">Nicola <italic>et al.</italic> 2005</xref>; <xref ref-type="bibr" rid="bibr14-1759720X13491853">Roubille and Tardif, 2013</xref>; <xref ref-type="bibr" rid="bibr17-1759720X13491853">Solomon <italic>et al.</italic> 2003</xref>]: a recent meta-analysis highlighted an increased risk of all CVDs of 48% in RA, as well as of myocardial infarction of 68% and of strokes of 41% [<xref ref-type="bibr" rid="bibr1-1759720X13491853">Avina-Zubieta <italic>et al.</italic> 2012</xref>]. Over the past decade, inflammation appeared to be the cornerstone of both atherosclerosis and RA. Indeed, atherosclerosis is no longer considered a condition in which lipids are being deposited passively in the arterial wall but rather fully recognized as an inflammatory, dynamic and complex disease involving multiple cell types, including inflammatory cells as well as endothelial and smooth muscle cells [<xref ref-type="bibr" rid="bibr8-1759720X13491853">Newby, 2010</xref>; <xref ref-type="bibr" rid="bibr13-1759720X13491853">Roubille <italic>et al.</italic> 2013c</xref>; <xref ref-type="bibr" rid="bibr15-1759720X13491853">Shah, 2009</xref>]. RA has long been recognized as a systemic inflammatory syndrome with several extra-articular manifestations such as interstitial lung disease and vasculitis. However, these features do not occur in all RA patients. In contrast, vascular inflammation and accelerated atherosclerosis may affect a larger RA population, probably all RA patients, especially in the early stage of the disease, as pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF-alpha), interleukin (IL)-1 and IL-6 as well as B cells contribute to the pathogenesis of both atherosclerosis and RA [<xref ref-type="bibr" rid="bibr5-1759720X13491853">Hansson, 2005</xref>]. Moreover, traditional cardiovascular risk factors should not be overlooked. Hence, assessment and management of cardiovascular risk factors is recommended for RA patients [<xref ref-type="bibr" rid="bibr6-1759720X13491853">Haraoui <italic>et al.</italic> 2012</xref>; <xref ref-type="bibr" rid="bibr10-1759720X13491853">Peters <italic>et al.</italic> 2010</xref>]. The treatment goal should be to achieve remission or at least low disease activity as early as possible [<xref ref-type="bibr" rid="bibr16-1759720X13491853">Smolen <italic>et al.</italic> 2010</xref>], not only to lead to better structural and functional outcomes, but also to reduce the cardiovascular risk [<xref ref-type="bibr" rid="bibr10-1759720X13491853">Peters <italic>et al.</italic> 2010</xref>].</p>
<p>In this issue, van den Oever and colleagues review the management of cardiovascular risk in RA. First, they present the main pathophysiological links between RA and the excess cardiovascular risk, emphasizing the early increased risk, even before RA diagnosis, and the contributing role of traditional risk factors, especially smoking which appears both as a potential predisposing factor for CVD but also a worsening factor for RA. Many studies have investigated the prevalence of traditional cardiovascular risk factors in RA (see Table 1 in the review by van den Oever and colleagues); nevertheless, traditional cardiovascular risk factors do not entirely account for the increased cardiovascular risk [<xref ref-type="bibr" rid="bibr3-1759720X13491853">del Rincon <italic>et al.</italic> 2001</xref>]. Therefore, a tight control of inflammation is required to prevent CVD in RA and the authors highlight the potential beneficial as well as deleterious impacts of RA therapy on cardiovascular events. Specific treatments targeting the inflammatory pathways are promising tools to control the burden of CVD in RA. Methotrexate, the cornerstone disease-modifying antirheumatic drug (DMARD) in RA, has been shown to decrease CVD [<xref ref-type="bibr" rid="bibr21-1759720X13491853">Westlake <italic>et al.</italic> 2010</xref>] and mortality in RA patients [<xref ref-type="bibr" rid="bibr19-1759720X13491853">Wasko <italic>et al.</italic> 2013</xref>]. Whether biological agents including TNF inhibitors (TNFi) are protective or not is open to discussion (<xref ref-type="bibr" rid="bibr12-1759720X13491853">Roubille <italic>et al.</italic> 2013b</xref>) and two systematic literature reviews identified so far a positive impact of TNFi on CVD in RA [<xref ref-type="bibr" rid="bibr2-1759720X13491853">Barnabe <italic>et al.</italic> 2011</xref>; <xref ref-type="bibr" rid="bibr20-1759720X13491853">Westlake <italic>et al.</italic> 2011</xref>]. An interesting study using positron emission tomography–computed tomography (PET-CT) scan recently demonstrated that RA patients had increased aortic inflammation which was reduced by TNFi [<xref ref-type="bibr" rid="bibr7-1759720X13491853">Maki-Petaja <italic>et al.</italic> 2012</xref>]. These results contrast with large clinical trials assessing TNFi in non-RA patients with heart failure which have been disappointing [<xref ref-type="bibr" rid="bibr12-1759720X13491853">Roubille <italic>et al.</italic> 2013b</xref>]. On the other hand, glucocorticoids and nonsteroidal anti-inflammatory drugs (NSAIDs) are generally considered harmful [<xref ref-type="bibr" rid="bibr11-1759720X13491853">Roubille <italic>et al.</italic> 2013a</xref>]. Furthermore, new drugs inhibiting or regulating inflammatory pathways, such as serine protease inhibitor SERP-1 and P-selectin inhibitors, remain of interest especially in atherosclerosis and further trials will address these issues [<xref ref-type="bibr" rid="bibr13-1759720X13491853">Roubille <italic>et al.</italic> 2013c</xref>].</p>
<p>The specific management of cardiovascular risk should combine control of disease activity (inflammation) and of traditional risk factors. It should become part of the daily practice in RA with the clinician focusing on achieving both inflammatory remission and optimal cardiovascular control [<xref ref-type="bibr" rid="bibr6-1759720X13491853">Haraoui <italic>et al.</italic> 2012</xref>]. The current practical issue for the routine management of RA patients is how to deal with CVD and prevention. The authors rightly point out the need for a coordinated effort on the part of both rheumatologists and primary care physicians. They recognize that systematic screening for cardiovascular risk factors is time-consuming and should involve a multidisciplinary team. The management of RA should involve a network of rheumatologists, general practitioners, cardiologists and specialized nurses. Educational programs should also promote awareness of risk and protective factors for CVD [<xref ref-type="bibr" rid="bibr18-1759720X13491853">Wartak <italic>et al.</italic> 2011</xref>]. Another important issue is what tools to use in assessing cardiovascular risk in an asymptomatic RA patient. Should we apply the 2010 American College of Cardiology Foundation/American Heart Association guidelines for the assessment of cardiovascular risk in asymptomatic adults [<xref ref-type="bibr" rid="bibr4-1759720X13491853">Greenland <italic>et al.</italic> 2010</xref>]? Should resting electrocardiography and/or echocardiography be done or more sophisticated tests such as stress test, assessment of arterial stiffness, or coronary artery calcium as is recommended in diabetes mellitus? In their review, van den Oever and colleagues draw a parallel between RA and diabetes mellitus, arguing that in both conditions, 15 years are added to the age of patients to express the excess cardiovascular risk. This similar cardiovascular excess risk between RA and diabetes emphasizes the significant cardiovascular burden in RA. Studies specifically designed to provide guidance will help clinicians in advising about lifestyle changes and the use of medical interventions to reduce patients’ cardiovascular risk in daily practice. We must recognize that RA is not just an arthritis disease but has huge consequences on major organs and physician should not treat a ‘disease’ but rather a ‘patient’ in a comprehensive way.</p>
</body>
<back>
<fn-group>
<fn fn-type="financial-disclosure">
<label>Funding</label>
<p>This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.</p>
</fn>
<fn fn-type="conflict">
<label>Conflict of interest statement</label>
<p>The authors declare that there are no conflicts of interest.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-1759720X13491853">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Avina-Zubieta</surname><given-names>J.</given-names></name>
<name><surname>Thomas</surname><given-names>J.</given-names></name>
<name><surname>Sadatsafavi</surname><given-names>M.</given-names></name>
<name><surname>Lehman</surname><given-names>A.</given-names></name>
<name><surname>Lacaille</surname><given-names>D.</given-names></name>
</person-group> (<year>2012</year>) <article-title>Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-analysis of observational studies</article-title>. <source>Ann Rheum Dis</source> <volume>71</volume>: <fpage>1524</fpage>-<lpage>1529</lpage>.</citation>
</ref>
<ref id="bibr2-1759720X13491853">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Barnabe</surname><given-names>C.</given-names></name>
<name><surname>Martin</surname><given-names>B.</given-names></name>
<name><surname>Ghali</surname><given-names>W.</given-names></name>
</person-group> (<year>2011</year>) <article-title>Systematic review and meta-analysis: anti-tumor necrosis factor alpha therapy and cardiovascular events in rheumatoid arthritis</article-title>. <source>Arthritis Care Res (Hoboken)</source> <volume>63</volume>: <fpage>522</fpage>-<lpage>529</lpage>.</citation>
</ref>
<ref id="bibr3-1759720X13491853">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>del Rincon</surname><given-names>I.</given-names></name>
<name><surname>Williams</surname><given-names>K.</given-names></name>
<name><surname>Stern</surname><given-names>M.</given-names></name>
<name><surname>Freeman</surname><given-names>G.</given-names></name>
<name><surname>Escalante</surname><given-names>A.</given-names></name>
</person-group> (<year>2001</year>) <article-title>High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors</article-title>. <source>Arthritis Rheum</source> <volume>44</volume>: <fpage>2737</fpage>-<lpage>2745</lpage>.</citation>
</ref>
<ref id="bibr4-1759720X13491853">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Greenland</surname><given-names>P.</given-names></name>
<name><surname>Alpert</surname><given-names>J.</given-names></name>
<name><surname>Beller</surname><given-names>G.</given-names></name>
<name><surname>Benjamin</surname><given-names>E.</given-names></name>
<name><surname>Budoff</surname><given-names>M.</given-names></name>
<name><surname>Fayad</surname><given-names>Z.</given-names></name><etal/>
</person-group>. (<year>2010</year>) <article-title>2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines</article-title>. <source>Circulation</source> <volume>122</volume>: <fpage>e584</fpage>-<lpage>e636</lpage>.</citation>
</ref>
<ref id="bibr5-1759720X13491853">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hansson</surname><given-names>G.</given-names></name>
</person-group> (<year>2005</year>) <article-title>Inflammation, atherosclerosis, and coronary artery disease</article-title>. <source>N Engl J Med</source> <volume>352</volume>: <fpage>1685</fpage>-<lpage>1695</lpage>.</citation>
</ref>
<ref id="bibr6-1759720X13491853">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Haraoui</surname><given-names>B.</given-names></name>
<name><surname>Liu</surname><given-names>P.</given-names></name>
<name><surname>Papp</surname><given-names>K.</given-names></name>
</person-group> (<year>2012</year>) <article-title>Managing cardiovascular risk in patients with chronic inflammatory diseases</article-title>. <source>Clin Rheumatol</source> <volume>31</volume>: <fpage>585</fpage>-<lpage>594</lpage>.</citation>
</ref>
<ref id="bibr7-1759720X13491853">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Maki-Petaja</surname><given-names>K.</given-names></name>
<name><surname>Elkhawad</surname><given-names>M.</given-names></name>
<name><surname>Cheriyan</surname><given-names>J.</given-names></name>
<name><surname>Joshi</surname><given-names>F.</given-names></name>
<name><surname>Ostor</surname><given-names>A.</given-names></name>
<name><surname>Hall</surname><given-names>F.</given-names></name><etal/>
</person-group>. (<year>2012</year>) <article-title>Anti-tumor necrosis factor-alpha therapy reduces aortic inflammation and stiffness in patients with rheumatoid arthritis</article-title>. <source>Circulation</source> <volume>126</volume>: <fpage>2473</fpage>-<lpage>2480</lpage>.</citation>
</ref>
<ref id="bibr8-1759720X13491853">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Newby</surname><given-names>D.</given-names></name>
</person-group> (<year>2010</year>) <article-title>Triggering of acute myocardial infarction: beyond the vulnerable plaque</article-title>. <source>Heart</source> <volume>96</volume>: <fpage>1247</fpage>-<lpage>1251</lpage>.</citation>
</ref>
<ref id="bibr9-1759720X13491853">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Nicola</surname><given-names>P.</given-names></name>
<name><surname>Maradit-Kremers</surname><given-names>H.</given-names></name>
<name><surname>Roger</surname><given-names>V.</given-names></name>
<name><surname>Jacobsen</surname><given-names>S.</given-names></name>
<name><surname>Crowson</surname><given-names>C.</given-names></name>
<name><surname>Ballman</surname><given-names>K.</given-names></name><etal/>
</person-group>. (<year>2005</year>) <article-title>The risk of congestive heart failure in rheumatoid arthritis: a population-based study over 46 years</article-title>. <source>Arthritis Rheum</source> <volume>52</volume>: <fpage>412</fpage>-<lpage>420</lpage>.</citation>
</ref>
<ref id="bibr10-1759720X13491853">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Peters</surname><given-names>M.</given-names></name>
<name><surname>Symmons</surname><given-names>D.</given-names></name>
<name><surname>McCarey</surname><given-names>D.</given-names></name>
<name><surname>Dijkmans</surname><given-names>B.</given-names></name>
<name><surname>Nicola</surname><given-names>P.</given-names></name>
<name><surname>Kvien</surname><given-names>T.</given-names></name><etal/>
</person-group>. (<year>2010</year>) <article-title>EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis</article-title>. <source>Ann Rheum Dis</source> <volume>69</volume>: <fpage>325</fpage>-<lpage>331</lpage>.</citation>
</ref>
<ref id="bibr11-1759720X13491853">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Roubille</surname><given-names>C.</given-names></name>
<name><surname>Martel-Pelletier</surname><given-names>J.</given-names></name>
<name><surname>Davy</surname><given-names>J.</given-names></name>
<name><surname>Haraoui</surname><given-names>B.</given-names></name>
<name><surname>Pelletier</surname><given-names>J.</given-names></name>
</person-group> (<year>2013a</year>) <article-title>Cardiovascular adverse effects of anti-inflammatory drugs</article-title>. <source>Antiinflamm Antiallergy Agents Med Chem</source> <volume>12</volume>: <fpage>55</fpage>-<lpage>67</lpage>.</citation>
</ref>
<ref id="bibr12-1759720X13491853">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Roubille</surname><given-names>C.</given-names></name>
<name><surname>Martel-Pelletier</surname><given-names>J.</given-names></name>
<name><surname>Haraoui</surname><given-names>B.</given-names></name>
<name><surname>Tardif</surname><given-names>J.</given-names></name>
<name><surname>Pelletier</surname><given-names>J.</given-names></name>
</person-group> (<year>2013b</year>) <article-title>Biologics and the cardiovascular system: a double-edged sword</article-title>. <source>Antiinflamm Antiallergy Agents Med Chem</source> <volume>12</volume>: <fpage>68</fpage>-<lpage>82</lpage>.</citation>
</ref>
<ref id="bibr13-1759720X13491853">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Roubille</surname><given-names>F.</given-names></name>
<name><surname>Kritikou</surname><given-names>E.</given-names></name>
<name><surname>Roubille</surname><given-names>C.</given-names></name>
<name><surname>Tardif</surname><given-names>J.</given-names></name>
</person-group> (<year>2013c</year>) <article-title>Emerging anti-inflammatory therapies for atherosclerosis</article-title>. <source>Curr Pharm Des</source>, in press.</citation>
</ref>
<ref id="bibr14-1759720X13491853">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Roubille</surname><given-names>F.</given-names></name>
<name><surname>Tardif</surname><given-names>J.</given-names></name>
</person-group> (<year>2013</year>) <article-title>Editorial: anti-inflammatory drugs and the heart</article-title>. <source>Antiinflamm Antiallergy Agents Med Chem</source> <volume>12</volume>: <fpage>2</fpage>.</citation>
</ref>
<ref id="bibr15-1759720X13491853">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Shah</surname><given-names>P.</given-names></name>
</person-group> (<year>2009</year>) <article-title>Inflammation and plaque vulnerability</article-title>. <source>Cardiovascular Drugs and Therapy</source> <volume>23</volume>: <fpage>31</fpage>-<lpage>40</lpage>.</citation>
</ref>
<ref id="bibr16-1759720X13491853">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Smolen</surname><given-names>J.</given-names></name>
<name><surname>Landewe</surname><given-names>R.</given-names></name>
<name><surname>Breedveld</surname><given-names>F.</given-names></name>
<name><surname>Dougados</surname><given-names>M.</given-names></name>
<name><surname>Emery</surname><given-names>P.</given-names></name>
<name><surname>Gaujoux-Viala</surname><given-names>C.</given-names></name><etal/>
</person-group>. (<year>2010</year>) <article-title>EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs</article-title>. <source>Ann Rheum Dis</source> <volume>69</volume>: <fpage>964</fpage>-<lpage>975</lpage>.</citation>
</ref>
<ref id="bibr17-1759720X13491853">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Solomon</surname><given-names>D.</given-names></name>
<name><surname>Karlson</surname><given-names>E.</given-names></name>
<name><surname>Rimm</surname><given-names>E.</given-names></name>
<name><surname>Cannuscio</surname><given-names>C.</given-names></name>
<name><surname>Mandl</surname><given-names>L.</given-names></name>
<name><surname>Manson</surname><given-names>J.</given-names></name><etal/>
</person-group>. (<year>2003</year>) <article-title>Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis</article-title>. <source>Circulation</source> <volume>107</volume>: <fpage>1303</fpage>-<lpage>1307</lpage>.</citation>
</ref>
<ref id="bibr18-1759720X13491853">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wartak</surname><given-names>S.</given-names></name>
<name><surname>Friderici</surname><given-names>J.</given-names></name>
<name><surname>Lotfi</surname><given-names>A.</given-names></name>
<name><surname>Verma</surname><given-names>A.</given-names></name>
<name><surname>Kleppel</surname><given-names>R.</given-names></name>
<name><surname>Naglieri-Prescod</surname><given-names>D.</given-names></name><etal/>
</person-group>. (<year>2011</year>) <article-title>Patients’ knowledge of risk and protective factors for cardiovascular disease</article-title>. <source>Am J Cardiol</source> <volume>107</volume>: <fpage>1480</fpage>-<lpage>1488</lpage>.</citation>
</ref>
<ref id="bibr19-1759720X13491853">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wasko</surname><given-names>M.</given-names></name>
<name><surname>Dasgupta</surname><given-names>A.</given-names></name>
<name><surname>Hubert</surname><given-names>H.</given-names></name>
<name><surname>Fries</surname><given-names>J.</given-names></name>
<name><surname>Ward</surname><given-names>M.</given-names></name>
</person-group> (<year>2013</year>) <article-title>Propensity-adjusted association of methotrexate with overall survival in rheumatoid arthritis</article-title>. <source>Arthritis Rheum</source> <volume>65</volume>: <fpage>334</fpage>-<lpage>342</lpage>.</citation>
</ref>
<ref id="bibr20-1759720X13491853">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Westlake</surname><given-names>S.</given-names></name>
<name><surname>Colebatch</surname><given-names>A.</given-names></name>
<name><surname>Baird</surname><given-names>J.</given-names></name>
<name><surname>Curzen</surname><given-names>N.</given-names></name>
<name><surname>Kiely</surname><given-names>P.</given-names></name>
<name><surname>Quinn</surname><given-names>M.</given-names></name><etal/>
</person-group>. (<year>2011</year>) <article-title>Tumour necrosis factor antagonists and the risk of cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review</article-title>. <source>Rheumatology (Oxford)</source> <volume>50</volume>: <fpage>518</fpage>-<lpage>531</lpage>.</citation>
</ref>
<ref id="bibr21-1759720X13491853">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Westlake</surname><given-names>S.</given-names></name>
<name><surname>Colebatch</surname><given-names>A.</given-names></name>
<name><surname>Baird</surname><given-names>J.</given-names></name>
<name><surname>Kiely</surname><given-names>P.</given-names></name>
<name><surname>Quinn</surname><given-names>M.</given-names></name>
<name><surname>Choy</surname><given-names>E.</given-names></name><etal/>
</person-group>. (<year>2010</year>) <article-title>The effect of methotrexate on cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review</article-title>. <source>Rheumatology (Oxford)</source> <volume>49</volume>: <fpage>295</fpage>-<lpage>307</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>